Non-Invasive Assessment Of Glymphatic Flow And Neurodegeneration From A Wearable Device

Abstract

A computer-implemented method and system includes accessing neurophysiological and neurovascular data recorded during sleep. A function mapping is executed from said neurophysiological and neurovascular data to a target that is one of a glymphatic flow marker, a molecular analysis marker of neurodegeneration, or a neuroimaging marker of neurodegeneration. A target prediction model is output based on the function mapping. The target prediction model can receive new neurophysiological and neurovascular data and output a predicted marker of neurodegeneration.

What is claimed: 
     
         1 . A brain monitoring system comprising:
 a left sensor comprising left electrodes that collect from a patient's head during sleep left side transcranial impedance data associated with a pharmaceutical intervention;   a right sensor comprising right electrodes that collect from the patient's head during sleep right side transcranial impedance data associated with the pharmaceutical intervention; and   a data module that:
 receives the left side transcranial impedance data from the left sensor, 
 receives the right side transcranial impedance data from the right sensor, wherein the left side and right side transcranial impedance data provide an indication of cranial interstitial fluid flow during sleep for the patient undergoing the pharmaceutical intervention, 
 applies the left side and right side transcranial impedance data to a prediction model, the prediction model based upon a function mapping to a target marker of glymphatic flow, and 
 outputs a measure of a therapeutic effect on glymphatic flow due to the pharmaceutical intervention. 
   
     
     
         2 . The brain monitoring system of  claim 1 , wherein the data module performs a second function mapping from the target marker of glymphatic flow to a target that is one of a molecular analysis marker of neurodegeneration or a neuroimaging marker of neurodegeneration. 
     
     
         3 . The brain monitoring system of  claim 2 , wherein the prediction model is created from prior molecular analysis markers of neurodegeneration or neuroimaging markers of neurodegeneration collected from a population of patients. 
     
     
         4 . The brain monitoring system of  claim 3 , wherein the data module further outputs a measure of neurodegeneration. 
     
     
         5 . The brain monitoring system of  claim 1 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for titration and continued treatment with the pharmaceutical intervention or a second pharmaceutical intervention. 
     
     
         6 . The brain monitoring system of  claim 1 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for inclusion in a clinical trial designed to determine dose and measure efficacy of the pharmaceutical intervention or a second pharmaceutical intervention. 
     
     
         7 . The brain monitoring system of  claim 1 , further comprising an input device that receives data describing the pharmaceutical intervention. 
     
     
         8 . The brain monitoring system of  claim 1 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for administration and timing of said administration of a second pharmaceutical intervention. 
     
     
         9 . The brain monitoring system of  claim 8 , wherein the second pharmaceutical intervention is administered directly into cerebrospinal fluid. 
     
     
         10 . The brain monitoring system of  claim 8 , further comprising an input device that receives data describing the second pharmaceutical intervention. 
     
     
         11 . A method of using a brain monitoring system, the method comprising:
 collecting from a patient's head during sleep, with a left sensor comprising left electrodes, left side transcranial impedance data associated with a pharmaceutical intervention;   collecting from the patient's head during sleep, with a right sensor comprising right electrodes, right side transcranial impedance data associated with the pharmaceutical intervention;   wherein the left side and right side transcranial impedance data provide an indication of cranial interstitial fluid flow during sleep for the patient undergoing the pharmaceutical intervention,   applying, by a data module of the brain monitoring system, the left side and right side transcranial impedance data to a prediction model, the prediction model based upon a function mapping to a target marker of glymphatic flow, and   outputting, by the data module, a measure of a therapeutic effect on glymphatic flow due to the pharmaceutical intervention.   
     
     
         12 . The method of  claim 11 , further comprising: applying, by the data module, a second function mapping from the target marker of glymphatic flow to a target that is one of a molecular analysis marker of neurodegeneration or a neuroimaging marker of neurodegeneration. 
     
     
         13 . The method of  claim 12 , wherein the prediction model is created from prior molecular analysis markers of neurodegeneration or neuroimaging markers of neurodegeneration collected from a population of patients. 
     
     
         14 . The method of  claim 13 , wherein the data module further outputs a measure of neurodegeneration. 
     
     
         15 . The method of  claim 11 , further comprising: inputting to the data module data describing the pharmaceutical intervention. 
     
     
         16 . The method of  claim 11 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for titration and continued treatment with the pharmaceutical intervention or a second pharmaceutical intervention. 
     
     
         17 . The method of  claim 11 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for inclusion in a clinical trial designed to determine dose and measure efficacy of the pharmaceutical intervention or a second pharmaceutical intervention. 
     
     
         18 . The method of  claim 11 , wherein the therapeutic effect on glymphatic flow due to the pharmaceutical intervention is used as a condition for administration and timing of said administration of a second pharmaceutical intervention. 
     
     
         19 . The method of  claim 18 , wherein the second pharmaceutical intervention is administered directly into cerebrospinal fluid. 
     
     
         20 . The method of  claim 18 , further comprising an input device that receives data describing the second pharmaceutical intervention.